bioRxivMolecular BiologyPreprint
LGR5-high colorectal cancer defines a Wnt-active stem-like state with multimodal therapeutic vulnerabilities
Lucía Paniagua‐Herranz, Alejandro FeitoiD, Cristian PrivatiD, Luis Álvarez‐CarrióniD, Bernard Doger, Andrés R. TejedoriD, Juan Antonio Ardua, Verónica AlonsoiD, Cristina Nieto‐JiméneziD, Carlos Alonso‐MorenoiD, Victor MorenoiD, Emiliano CalvoiD, Balázs GyőrffyiD, Jorge R. EspinosaiD, Alberto OcañaiD
Abstract
Leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) marks a stem-like colorectal cancer population but is difficult to target directly because of its expression in normal intestinal stem cells. Here, we integrated transcriptomic, somatic mutation, and copy-number data from 396 colorectal tumors to define the LGR5-high molecular state and identify therapeutic vulnerabilities through modality-matched tractability analysis. LGR5-high tumors displayed a coordinated Wnt-active, stem-like transcriptional program associated with extracellular matrix remodeling, APC mutations, and IGF2 amplification, yet lacked selective genetic dependencies among the identified genes. We therefore assessed candidate targets across three complementary dimensions: surface accessibility, structural ligandability, and biomolecular condensate behavior. ENPP3 emerged as the strongest candidate for antibody-based delivery, combining tumor-associated expression, an accessible ectodomain, internalization capacity, and clinical antibody-drug conjugate precedent. PLCB4 showed the strongest structural ligandability, with independent algorithms identifying its catalytic site and additional predicted cavities. NKD1 lacked conventional ligandable pockets but formed RNA-stabilized condensates and partitioned into DVL2-AXIN1 assemblies, reducing AXIN1 self-association and DVL2-AXIN1 contacts in molecular simulations. Together, these findings define LGR5-high colorectal cancer as a therapeutically tractable molecular state and establish a modality-matched framework for translating tumor-associated signatures into experimentally testable therapeutic hypotheses.
- organism: human
- assay: bulk RNA-seq
- research focus: differential expression
- research focus: drug response / drug discovery
- approach: statistical model
- approach: simulation
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- LGR5 targeting molecules as therapeutic agents for multiple cancer types
H.-C. Chen, N. Mueller, … M. de la Roche·bioRxiv·Sep 1, 2022
- Antibody-drug conjugate combination therapy targeting LGR5 and MET with different payloads enhances efficacy in preclinical colorectal cancer models
Shraddha Subramanian, Peyton C. High, … Kendra S. Carmon·bioRxiv·Oct 18, 2026
- Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models
Peyton C. High, Zhengdong Liang, … Kendra S. Carmon·Cell Reports MedicinePeer-reviewed·Sep 23, 2025
- Loss of LGR5 through plasticity or gene ablation is associated with therapy resistance and enhanced MET-STAT3 signaling in colorectal cancer cells
T. A. Posey, J. Jacob, … K. S. Carmon·bioRxiv·Mar 1, 2022
- Membrane to cortex attachment determines different mechanical phenotypes in LGR5+ and LGR5- colorectal cancer cells
S. Conti, V. Venturini, … X. Trepat·bioRxiv·Dec 4, 2023
- An antibody-drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancer
J. Jacob, L. E. Francisco, … K. S. Carmon·bioRxiv·Aug 11, 2022